RecruitingNCT07485114

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Studying Chromophobe renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daniel Keizman
Intervention
Serum Gal-3 level, blood count and chemistry included liver function(diagnostic_test)
Enrollment
300 enrolled
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07485114 on ClinicalTrials.gov

Other trials for Chromophobe renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Chromophobe renal cell carcinoma

← Back to all trials